Lunaphore and Indica Labs combine spatial biology and pathology imaging platforms
May 13, 2022 -- Lunaphore and Indica Labs have partnered on the development of a biological research tool involving software from both companies. This new solution will involve a combination of Lunaphore’s Comet spatial biology platform and Indica Labs’ Halo digital pathology image analysis software. Read More
Avantor and Cytovance enter into plasmid manufacturing agreement
May 11, 2022 -- Avantor and Cytovance Biologics have entered into an agreement to advance the manufacturing of plasmids. This agreement will combine Avantor’s expertise in providing cell and gene therapy materials with Cytovance’s plasmid DNA manufacturing capabilities. Read More
Study of T-cell behavior predicts therapeutic differences in cancer outcomes
May 10, 2022 -- Researchers at Weill Cornell Medicine have published a study in Cancer Cell revealing a novel insight on the role of T cells in cancer therapies. The study focused on comparing the differences in behaviors of T cells in immunotherapy for metastatic melanoma to treatment outcomes. Read More
Lunaphore launches Comet antibody instrument in U.K.
May 9, 2022 -- Lunaphore installed its Comet Primary Antibodies instrument at Propath U.K., the first contract research organization in Europe to offer the service. Read More
Dotmatics debuts new antibody discovery software
May 9, 2022 -- Dotmatics has launched a new end-to-end software and cloud-based data management package: Biology Solution for Antibody Discovery. Read More
RedShift BioAnalytics releases biomolecule characterization technology
May 4, 2022 -- RedShift BioAnalytics has launched its novel Apollo technology for advanced microfluidic modulation spectroscopy. This technology enables highly sensitive and precise measurement of biomolecules with improved efficiency and decreased sample volume compared to the company's previous AQS3 pro structural analysis technology. Read More
Biocytogen partners with Merck to evaluate novel antibodies
May 2, 2022 -- Biocytogen Pharmaceuticals has entered into an evaluation and option agreement with Merck KGaA to evaluate Biocytogen’s antibodies. The agreement will give Merck KGaA the license to assess these antibodies against three specified targets. Read More
BeiGene establishes manufacturing and clinical R&D center in Hopewell, NJ
May 2, 2022 -- BeiGene has broken ground on a new manufacturing and clinical R&D center to be built at the Princeton West Innovation Campus located in Hopewell, NJ. The planned 400,000-sq-ft facility will be constructed to support the manufacturing of various biologics produced by BeiGene. Read More
Artiva announces new NK agreement with Merck
April 21, 2022 -- Artiva Biotherapeutics entered into an agreement with Merck to evaluate the therapeutic potential of Artiva's clinical-grade AB-101 natural killer (NK) cells from its AlloNK platform for assessment in combination with tri-specific NK-cell engager candidates. Read More
Gennao Bio presents results for gene monoclonal antibody platform at AACR 2022
April 19, 2022 -- Gennao Bio is highlighting results presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting on its nonviral gene monoclonal antibody platform in multiple solid tumor models. Read More
International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter